
November 1, 2017 - By Maria Brooks
AstraZeneca plc (ADR) (AZN) formed multiple top with $37.61 target or 9.00% above today’s $34.50 share price. AstraZeneca plc (ADR) (AZN) has $85.27B valuation. The stock increased 2.16% or $0.73 during the last trading session, reaching $34.5. About 52,400 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since November 1, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.Kewaunee Scientific Corporation is engaged in the design, manufacture and installation of laboratory, healthcare and technical furniture products. The company has market cap of $77.34 million. The Company’s products include steel, wood and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. It has a 17.88 P/E ratio. It operates through two divisions: Domestic and International.The stock increased 0.71% or $0.2 on October 31, reaching $28.5. About shares traded. Kewaunee Scientific Corporation (KEQU) has risen 38.94% since November 1, 2016 and is uptrending. It has outperformed by 22.24% the S&P500.Perritt Capital Management Inc holds 0.32% of its portfolio in Kewaunee Scientific Corporation for 49,869 shares. North Star Investment Management Corp. owns 82,625 shares or 0.28% of their US portfolio. Moreover, Salem Investment Counselors Inc has 0.16% invested in the company for 55,325 shares. The Wisconsin-based Morgan Dempsey Capital Management Llc has invested 0.11% in the stock. Seizert Capital Partners Llc, a Michigan-based fund reported 22,118 shares.Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 9. They expect $0.50 EPS, down 62.12% or $0.82 from last year’s $1.32 per share. AZN’s profit will be $1.24 billion for 17.25 P/E if the $0.50 EPS becomes a reality. After $0.87 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -42.53% negative EPS growth. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.


var data = "63557954";
document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="8925061741"></ins>')

(adsbygoogle = window.adsbygoogle || []).push({});
(adsbygoogle = window.adsbygoogle || []).push({});